CureVac AG : Curevac is a private German mRNA company with a diversified pipeline, and three lead programs in ph1: CV8102 (various cancer indications), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19) provides further technology validation. Other companies in the space: MRNA, TBIO, BNTX.
• Lead Programs:
o CV8102 (melanoma, adenoidcystic carcinoma, sq cell cancer of skin and H&N) in Ph 1
 Ph1 readout mid-2021
 Ph2 initiation 2H 2021
o CV9202 (NSCLC) in Ph 1
o CV7202 (Rabies) in Ph 1
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Autoimmune, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Platform Technology, Vaccine
Website:
Profiles:
Address:
Paul-Ehrlich-Straße 15
Tübingen, Baden-Wurttemberg 72076
Germany

Company Participants at Solebury Trout Management Access SF 2020

  • Daniel L. Menichella, Chief Executive Officer
  • Franz-Werner Haas, Acting Chief Executive Officer, Chief Operating Officer
  • Ingmar Hoerr, Chairman
  • Joseph West
  • Mariola Fotin-Mleczek, CSO
  • Pierre Kemula, CFO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.